摘要
目的探讨曲美他嗪佐治冠心病的有效性和安全性。方法选取我院2010年4月至2013年9月间收治的60例冠心病患者,随机分为对照组和观察组各30例,对照组给予阿托伐他汀治疗,观察组给予阿托伐他汀联合曲美他嗪治疗。比较两组治疗前后运动持续时间、诱发心绞痛发作时间、ST段下移1 mm时间、治疗总有效率和不良反应发生率的差异。结果治疗后观察组运动持续时间、诱发心绞痛发作时间和ST段下移1 mm时间均较对照组显著延长(P<0.05);观察组的治疗总有效率为93.3%,显著高于对照组的70.0%(P<0.05);两组患者均无严重不良反应发生(P>0.05)。结论曲美他嗪佐治冠心病疗效确切,可有效改善心功能,且不良反应少。
Objective To investigate the clinical efficacy and safety of trimetazidine for the adjuvant treatment of coronary heart disease. Methods 60 patients with coronary heart disease in our hospital from April 2010 to September 2013 were randomly divided into control group and observation group, with 30 cases in each group. Patients in the control groL,p were 1：reared with atorvastatin, while patients in the observation group were treated with atorvastatin combined with trimetazidine. The exercise duration time, induced angina onset time, 1 mm ST segment depression time before and after treatment, the total effective rate and incidence of adverse reactions of two groups were compared. Results The exercise duration time, induced angina onset time and 1 mm ST segment depression time after treatment of observation group were significantly longer than those of control group （all P 〈0.05）. The total effective rate of observation group was 93.3%, significantly higher than 70.0% of control group （P 〈0.05）. No serious adverse reaction was found in both groups （P 〉0.05）. Conclusions Trimetazidine for the adjuvant treatment of coronary heart disease has exact effect. It can effectively improve the cardiac function with few adverse reactions.
出处
《临床医学工程》
2014年第4期457-458,共2页
Clinical Medicine & Engineering
关键词
曲美他嗪
阿托伐他汀
冠心病
Trimetazidine
Atorvastatin
Coronary heart disease
